NCT04291300View on ClinicalTrials.gov

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Salivary Gland CancerSalivary Duct CarcinomaAdenoid Cystic Carcinoma
Interventions
DRUG

Lutetium-177-PSMA-I&T

4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.

Trial Locations (1)

6500HB

Radboudumc, Nijmegen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER

NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients | Biotech Hunter | Biotech Hunter